Oncotelic Therapeutics, Inc. (OTLC)

Market Cap	21.38M -19.5%
Revenue (ttm)	n/a
Net Income	247.38M
EPS	0.58
Shares Out	443.48M
PE Ratio	0.08
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,500
Open	0.0538
Previous Close	0.0482
Day's Range	0.0471 - 0.0538
52-Week Range	0.0150 - 0.1100
Beta	-0.32
Analysts	Strong Buy
Price Target	4.00 (+8,392.57%)
Earnings Date	Aug 13, 2026

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer. It is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-β2, which is in phase 3 clinical trials for pancreatic cancer, melanoma, and glioblastoma, as well as for the treatment of various viru...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Vuong Trieu
• Employees: 43
• Stock Exchange: OTCMKTS
• Ticker Symbol: OTLC

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 15, 2026

Data Sources Report a data error